Medicus Pharma (NASDAQ:MDCX – Get Free Report) was upgraded by investment analysts at Brookline Capital Management to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.
Separately, Maxim Group initiated coverage on shares of Medicus Pharma in a research report on Tuesday, December 17th. They issued a “buy” rating and a $10.00 target price on the stock.
Read Our Latest Stock Report on MDCX
Medicus Pharma Price Performance
Medicus Pharma Company Profile
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Read More
- Five stocks we like better than Medicus Pharma
- What is the S&P/TSX Index?
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- Golden Cross Stocks: Pattern, Examples and Charts
- 2 Drone Stocks Surging from Increased Media Attention
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
